Merck Acquires Cancer Specialist Springworks in Major Deal

The Merck Group, based in Darmstadt, is significantly enhancing its oncology portfolio through a strategic acquisition in the United States. The pharmaceutical giant has agreed to acquire Springworks Therapeutics, a biotech company focused on developing therapies for rare tumors, for approximately EUR3 billion, translating to $47 per share.

Merck's CEO emphasized that this acquisition represents a pivotal moment for the company, reinforcing its commitment to the healthcare sector, particularly in the area of rare cancers. The deal is expected to be finalized in the second half of the year, pending approval from Springworks' shareholders and regulatory bodies.

Springworks Therapeutics, established in 2017 as a spinoff from Pfizer, specializes in treatments for rare tumors and blood cancers. The company has already secured approval for a drug targeting advanced soft tissue tumors in the U.S. and is pursuing potential approval in the European Union. Merck aims to establish a leading position in the rare tumor market, which it identifies as a significant area with unmet therapeutic needs.

The acquisition comes at a time when Merck's pharmaceutical division is under pressure to deliver innovative therapies following setbacks with several key drug candidates in clinical trials. Despite recent growth in the division, the company has been actively seeking partnerships and acquisitions to bolster its pipeline. The CEO noted that Merck is positioned to pursue further significant transactions even after acquiring Springworks.

Historically, Merck's last major acquisition was in 2019, when it purchased Versum Materials, a U.S. semiconductor supplier, for around EUR5.8 billion. The largest acquisition to date was the purchase of Sigma-Aldrich in 2015 for EUR13 billion, which significantly expanded Merck's presence in the laboratory supplies market.